User login
Of the new medications set to be released in 2015, three cardiovascular drugs could achieve “blockbuster” sales of over $1 billion by 2019, according to a report from Thomson Reuters.
Of the “Drugs to Watch in 2015,” those for the cardiovascular system are projected to reach nearly $10 billion by 2019.
Two PCSK9 inhibitors, alirocumab and evolocumab, are expected to gain Food and Drug Administration approval as early as this summer and become the next cholesterol-lowering blockbusters. Each has shown unprecedented LDL cholesterol lowering as well as reductions in adverse cardiovascular events, and the report projects sales of $4.4 billion and $1.9 billion, respectively. This $2.5-billion disparity between evolocumab and alirocumab (trade name Praluent) may be explained by alirocumab’s expected arrival on the market a month sooner.
The novel heart failure drug LCZ-696 (sacubitril and valsartan) has projected sales of $3.7 billion through 2019, Thomson Reuters said. The angiotensin receptor neprilysin inhibitor reduced cardiovascular death and heart failure hospitalization by 20%, compared with enalapril, in heart failure patients in the large PARADIGM-HF trial.
Overall, 11 drugs are expected to reach $1 billion in sales by 2019, many more than the three blockbusters predicted from the 2014 stock of drugs. With projected sales of nearly $5.7 billion for 2019, the melanoma drug Opdivo (nivolumab) is at the head of a large 2015 blockbuster class. However, the two highest-selling new drugs from 2014, Sovaldi (sofosbuvir) and Harvoni (sofosbuvir plus ledipasvir) – both HCV drugs – are each predicted to reach sales of over $10 billion by 2017, far exceeding anything from 2015, the report said.
With estimated sales of $2.8 billion, the breast cancer drug Ibrance (palbociclib) is the second oncologic drug making the blockbuster list, with the first noncancer or non-CV drug – lumacaftor plus ivacaftor for cystic fibrosis – rounding out the top five with projected sales of $2.7 billion by 2019.
The Thomson Reuters Market Insight Report used data collected from 2013 through early February 2015.
Of the new medications set to be released in 2015, three cardiovascular drugs could achieve “blockbuster” sales of over $1 billion by 2019, according to a report from Thomson Reuters.
Of the “Drugs to Watch in 2015,” those for the cardiovascular system are projected to reach nearly $10 billion by 2019.
Two PCSK9 inhibitors, alirocumab and evolocumab, are expected to gain Food and Drug Administration approval as early as this summer and become the next cholesterol-lowering blockbusters. Each has shown unprecedented LDL cholesterol lowering as well as reductions in adverse cardiovascular events, and the report projects sales of $4.4 billion and $1.9 billion, respectively. This $2.5-billion disparity between evolocumab and alirocumab (trade name Praluent) may be explained by alirocumab’s expected arrival on the market a month sooner.
The novel heart failure drug LCZ-696 (sacubitril and valsartan) has projected sales of $3.7 billion through 2019, Thomson Reuters said. The angiotensin receptor neprilysin inhibitor reduced cardiovascular death and heart failure hospitalization by 20%, compared with enalapril, in heart failure patients in the large PARADIGM-HF trial.
Overall, 11 drugs are expected to reach $1 billion in sales by 2019, many more than the three blockbusters predicted from the 2014 stock of drugs. With projected sales of nearly $5.7 billion for 2019, the melanoma drug Opdivo (nivolumab) is at the head of a large 2015 blockbuster class. However, the two highest-selling new drugs from 2014, Sovaldi (sofosbuvir) and Harvoni (sofosbuvir plus ledipasvir) – both HCV drugs – are each predicted to reach sales of over $10 billion by 2017, far exceeding anything from 2015, the report said.
With estimated sales of $2.8 billion, the breast cancer drug Ibrance (palbociclib) is the second oncologic drug making the blockbuster list, with the first noncancer or non-CV drug – lumacaftor plus ivacaftor for cystic fibrosis – rounding out the top five with projected sales of $2.7 billion by 2019.
The Thomson Reuters Market Insight Report used data collected from 2013 through early February 2015.
Of the new medications set to be released in 2015, three cardiovascular drugs could achieve “blockbuster” sales of over $1 billion by 2019, according to a report from Thomson Reuters.
Of the “Drugs to Watch in 2015,” those for the cardiovascular system are projected to reach nearly $10 billion by 2019.
Two PCSK9 inhibitors, alirocumab and evolocumab, are expected to gain Food and Drug Administration approval as early as this summer and become the next cholesterol-lowering blockbusters. Each has shown unprecedented LDL cholesterol lowering as well as reductions in adverse cardiovascular events, and the report projects sales of $4.4 billion and $1.9 billion, respectively. This $2.5-billion disparity between evolocumab and alirocumab (trade name Praluent) may be explained by alirocumab’s expected arrival on the market a month sooner.
The novel heart failure drug LCZ-696 (sacubitril and valsartan) has projected sales of $3.7 billion through 2019, Thomson Reuters said. The angiotensin receptor neprilysin inhibitor reduced cardiovascular death and heart failure hospitalization by 20%, compared with enalapril, in heart failure patients in the large PARADIGM-HF trial.
Overall, 11 drugs are expected to reach $1 billion in sales by 2019, many more than the three blockbusters predicted from the 2014 stock of drugs. With projected sales of nearly $5.7 billion for 2019, the melanoma drug Opdivo (nivolumab) is at the head of a large 2015 blockbuster class. However, the two highest-selling new drugs from 2014, Sovaldi (sofosbuvir) and Harvoni (sofosbuvir plus ledipasvir) – both HCV drugs – are each predicted to reach sales of over $10 billion by 2017, far exceeding anything from 2015, the report said.
With estimated sales of $2.8 billion, the breast cancer drug Ibrance (palbociclib) is the second oncologic drug making the blockbuster list, with the first noncancer or non-CV drug – lumacaftor plus ivacaftor for cystic fibrosis – rounding out the top five with projected sales of $2.7 billion by 2019.
The Thomson Reuters Market Insight Report used data collected from 2013 through early February 2015.
